Course Catalog

Expert Illustrations & Commentaries™: Outlining the Role of BTK inhibitors in Multiple Sclerosis

Stephen Krieger, MD, FAAN; Enrique Alvarez, MD, PhD

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Benjamin P. Levy, MD; Stephanie McDonald, FNP-BC, AO...

Advancing Access to High-Quality, Biomarker-Guided Care for All Patients With mNSCLC

Narjust Florez, MD, FASCO; Darren Luon, PharmD, BCOP; Dipesh Uprety, MD; Colton Zwart PharmD, BCOP

Community Practice Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma

Geoffrey Ku, MD; Sunnie S. Kim, MD

Project ECHO®: Extending the Impact of CAR T—Practical Approaches to Long-Term Care in the Community

Jesús G. Berdeja, MD; Nicholas Barkemeyer, PA-C, MPAS; Michael Byrne, DO, FACP

SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care

Geoffrey Y. Ku, MD; Sunnie S. Kim, MD

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Assessing Corneal Sensitivity in Neurotrophic Keratitis

Project ECHO®: Navigating CRS and ICANS Related to CAR T-Cell Therapy: Prevention, Grading, and Management in Practice

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Kyle T. Roberts, PA-C

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Krish Patel, MD; Matthew Ulrickson, MD

Project ECHO®: Building Bridges in CAR T Care: Collaborative Pathways to Improve Patient Access and Navigate Referrals

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Katie Marcucci, DMSc, PA-C, CPAAPA; Xiaoxiao Zhang, A...

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

John O. Mascarenhas, MD; Claire Harrison, MD, DM, FRCP, FRCPath; Raajit Rampal, MD, PhD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Lori A. Leslie, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Krish Patel, MD; Tara Graff, DO, MS

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Krish Patel, MD; Girish Kunapareddy, MD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Krish Patel, MD; Premila Malhotra, MD

Clinical Crossroads™: The Importance of Considering Lambert-Eaton Myasthenic Syndrome (LEMS) in the Differential Diagnosis

Katherine Ruzhansky, MD, MS; Perry Shieh, MD, PhD, FAAN

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

From Chair to Care Plan—Applying Evidence to Patient-Centered Management

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

Timing Is Everything—Onset, Duration, and Dosing in Real-World Care

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

From Dropout to Long-Term Wear—A Case-Based Approach to Personalized Contact Lens Care

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Expanding the Fit—Mastering Toric and Multifocal Success in Complex Patients

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

Modality Matters—Optimizing Contact Lens Selection for Real-World Wear

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Burst CME™ Part VI: What Does this all Mean for Patients with IgAN?

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part V: Complement Inhibitors in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part IV: Anti-CD38 Therapies in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part III: BAFF and APRIL Directed Therapies in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part II: Endothelin A Receptor Antagonists in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part I: What’s New in IgAN?

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™: Elevating Care in the Management of IgA Nephropathy (IgAN) Nursing Track

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Adam Brufsky, MD, PhD; Manali Bhave, MD

Project ECHO®: CAR T in Practice: Identifying Eligible Patients Across Hematologic Malignancies

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP

Beyond the Itch—Decoding the Immunopathology of Allergic Conjunctivitis

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS

Advances in™ Generalized Myasthenia Gravis: Continuing the Quest for Novel Therapies

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

Katherine E. Di Palo, PharmD, MBA, MS; Nancy M. Albert, PhD, APRN-CCNS, CHFN, CCRN, NE-BC, FCCM, FAH...

BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Adam Brufsky, MD, PhD; Manali Bhave, MD

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Enriqueta Felip, MD, PhD; Justin Gainor, MD; Julia Rotow, MD; Urs Weber, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan...

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Jason Aboudi Mouabbi, MD

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, MD

Selecting an Optimal Therapeutic Strategy for the Management of Atopic Dermatitis in Young Children

Elaine Siegfried, MD; Lawrence F. Eichenfield, MD

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; Seth A. Wander, MD, PhD

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

Scott Kahan, MD, MPH; Robert F. Kushner, MD, MS, DABOM; Christopher D. Still, DO, FACP, FTOS

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

February 6, 2027

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Tarantino, MD, PhD

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; Paula A. Ugalde Figueroa, MD